Candel Therapeutics, Inc. (NASDAQ:CADL) Major Shareholder Sells $12,330.00 in Stock

Candel Therapeutics, Inc. (NASDAQ:CADL) major shareholder Estuardo Aguilar-Cordova sold 1,800 shares of the stock in a transaction dated Thursday, October 3rd. The stock was sold at an average price of $6.85, for a total transaction of $12,330.00. Following the transaction, the insider now directly owns 959,873 shares in the company, valued at $6,575,130.05. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Large shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Candel Therapeutics Trading Down 0.9 %

Shares of NASDAQ CADL opened at $6.65 on Friday. The company has a quick ratio of 1.62, a current ratio of 1.62 and a debt-to-equity ratio of 1.66. The stock’s 50 day moving average price is $6.24 and its two-hundred day moving average price is $6.52. Candel Therapeutics, Inc. has a 52-week low of $0.66 and a 52-week high of $14.30. The stock has a market capitalization of $197.88 million, a P/E ratio of -5.20 and a beta of -0.95.

Candel Therapeutics (NASDAQ:CADL) last posted its quarterly earnings results on Tuesday, August 13th. The company reported ($0.74) earnings per share (EPS) for the quarter. On average, analysts anticipate that Candel Therapeutics, Inc. will post -0.91 earnings per share for the current fiscal year.

Institutional Trading of Candel Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the business. Point72 DIFC Ltd acquired a new stake in shares of Candel Therapeutics during the 2nd quarter worth approximately $31,000. Rhumbline Advisers acquired a new position in shares of Candel Therapeutics during the second quarter valued at $143,000. Cubist Systematic Strategies LLC bought a new position in shares of Candel Therapeutics during the second quarter worth about $162,000. Finally, Bank of New York Mellon Corp acquired a new stake in shares of Candel Therapeutics in the 2nd quarter worth about $338,000. 13.93% of the stock is owned by institutional investors and hedge funds.

About Candel Therapeutics

Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.